Can we predict who will benefit most from biologics in severe asthma? A post-hoc analysis of two phase 3 trials

BACKGROUND: Individualized prediction of treatment response may improve the value proposition of advanced treatment options in severe asthma. This study aimed to investigate the combined capacity of patient characteristics in predicting treatment response to mepolizumab in patients with severe asthm...

Descripción completa

Detalles Bibliográficos
Autores principales: Chen, Wenjia, Reddel, Helen K., FitzGerald, J Mark, Beasley, Richard, Janson, Christer, Sadatsafavi, Mohsen
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2023
Materias:
Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10155396/
https://www.ncbi.nlm.nih.gov/pubmed/37131185
http://dx.doi.org/10.1186/s12931-023-02409-2

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10155396/
https://www.ncbi.nlm.nih.gov/pubmed/37131185
http://dx.doi.org/10.1186/s12931-023-02409-2

Ejemplares similares